This review will summarize recent evidence on the cardiovascular risks associated with GnRH agonists and antagonists and provide advice on the assessment and mitigation of cardiovascular risk for prostate cancer patients in clinical practice. This evidence concerns the gene GNRH1 and Familial prostate cancer.